Friday, March 29, 2024 1:17:00 PM
Recent AKBA News
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/08/2024 07:17:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 12:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 12:05:26 PM
- Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 11/07/2024 12:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 11/01/2024 08:05:00 PM
- Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights • PR Newswire (US) • 11/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/22/2024 12:05:56 PM
- Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis • PR Newswire (US) • 10/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2024 11:36:10 AM
- Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 • PR Newswire (US) • 10/15/2024 12:00:00 PM
- CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 • PR Newswire (US) • 10/10/2024 12:00:00 PM
- Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis • PR Newswire (US) • 10/07/2024 12:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 10/01/2024 08:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2024 04:15:10 AM
- Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis • PR Newswire (US) • 09/05/2024 12:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 09/03/2024 08:16:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/03/2024 08:07:59 PM
- Akebia Therapeutics to Present at Upcoming Investor Conferences • PR Newswire (US) • 08/26/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 11:52:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:06:18 AM
- Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 08/08/2024 11:00:00 AM
- Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights • PR Newswire (US) • 08/02/2024 12:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 08/01/2024 08:05:00 PM
- Akebia Therapeutics to Present at Upcoming Investor Conferences • PR Newswire (US) • 07/29/2024 12:00:00 PM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM